



FOR IMMEDIATE RELEASE

Jan van Heek Nominated to Supervisory Board of to-BBB

Leiden, the Netherlands, 13 January 2014 - [to-BBB](#), a biotechnology company that develops novel treatments for devastating brain disorders, has further strengthened its organization by appointing Mr. G. Jan Van Heek to its Supervisory Board. Mr. van Heek brings several decades of experience in the biotech industry from senior positions at Genzyme and Baxter and in boards of several biotech companies, including Amarin Corporation.

“As a board member I look forward to contribute to to-BBB’s development and growth,” says Jan van Heek. “With two clinical stage products and additional [pipeline](#) opportunities for brain diseases therapies, the company has tremendous potential for growth.”

Willem van Weperen, Chief Executive Officer of to-BBB, adds: “Jan’s industry experience in global drug development and commercialization will be very valuable to support the ambitious plans of the company. By adding a seasoned US-based board member with ties to the Netherlands, we are in a strong position to shape our global product development strategy”.

Jan van Heek is principal and partner in BioPoint Group, advising biotechnology and other healthcare companies in commercial strategy development, financing and business development activities. From 1991 through mid-2009, Mr. Van Heek was a member of Genzyme Corporation’s senior management team, reporting to the CEO. He established Genzyme’s European and international offices in the early 1990s before moving to the US to head the global Therapeutics Group. Jan van Heek has played a key role in building Genzyme’s broad portfolio of businesses and manufacturing structure worldwide. Prior to Genzyme, he held various management positions at Baxter Healthcare Corporation in Europe and the US. At Baxter his last position was VP/GM of the global Fenwal Division based in Deerfield, Illinois. Currently, Mr. Van Heek is a board member of Amarin Corporation, a cardiovascular drug development company. He also served on the boards of BioVex Inc., PanGenetics BV, ViaCell Corporation and Zelos Therapeutics. Jan van Heek succeeds Mr. Jaap Blaak on the to-BBB Supervisory Board as representative of Antea Participaties.

About to-BBB

to-BBB is a clinical stage biotechnology company developing novel treatments for devastating brain disorders, such as brain cancer and neuroinflammatory diseases. The Company combines existing drugs with to-BBB’s proprietary G-Technology® to enhance drug delivery across the blood-brain barrier. to-BBB currently has two products in clinical trials: its lead product 2B3-101 is in a Phase IIa trial in Europe and the US for the treatment of primary brain tumors as well as brain metastases; the second product 2B3-201 for MS relapses and other neuroinflammatory diseases entered a Phase I clinical study in December 2013.

to-BBB is based in the Netherlands and its subsidiary to-BBB Taiwan Ltd. is based in Taipei, Taiwan. Investors in to-BBB include Aescap Venture, Antea Participaties, Jonghoud International and the Industrial Bank of Taiwan Management Corporation (IBTM).

For more information:

Corporate Contacts:

Willem van Weperen, MSc, MBA
Chief Executive Officer

Phone: +31 71 33 222 51

E-mail: WillemVanWeperen@toBBB.com

to-BBB technologies BV

J.H. Oortweg 19
2333 CH Leiden
The Netherlands
www.toBBB.com

Sijme Zeilemaker, MSc
Business Development Manager

Phone: +31 71 33 222 56

E-mail: SijmeZeilemaker@toBBB.com

to-BBB technologies BV

J.H. Oortweg 19
2333 CH Leiden
The Netherlands
www.toBBB.com